The Effectiveness And Safety Advantages Of New Crown Vaccine In Guangzhou And Other Places Are Highlighted

Vaccination has become a race to end the epidemic and reshape the entire vaccine industry.

According to the latest data released by the National Health Commission, as of May 25, 2021, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps have reported 546.714 million doses of new coronavirus vaccine.

Previously, the China Center for Disease Control and Prevention said it expected that by next year, China's new crown vaccine could meet the internationally recognized standard of universal immunization, which means that 900 million to 1 billion people in China will be vaccinated with the new crown vaccine.

In this competition, the domestic new crown vaccine continued to perform brilliantly. On the 27th, China biology released the clinical data of the world's first phase III vaccine with 78.1% and 72.8% protective efficacy respectively.

Vaccination acceleration, track or tightening

Recently, the willingness of Guangzhou citizens to vaccinate new coronavirus vaccine continued to rise. Guangzhou Health Commission said that the current supply of new coronavirus vaccine in the city was sustained, which could meet the needs of the public in the near and long term.

According to the latest data released by the National Health Commission, as of May 25, 2021, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps have reported 546.714 million doses of new coronavirus vaccine.

It is worth mentioning that the U.S. Food and Drug Administration (FDA) said on Tuesday local time that if the company has not entered the discussion process of applying for emergency use authorization, the FDA may refuse to review and process new emergency use authorization requests for the new crown vaccine.

Since the outbreak of the new crown epidemic, the United States announced on March 13, last year that it began to enter a state of emergency. FDA approved more than 250 kinds of drugs, diagnostic reagents and medical devices through the emergency use authorization channels.

Some industry insiders told the 21st century economic report that this news has released a signal that the US FDA may be tightening up the market access channel of each new crown vaccine under the circumstances of various pharmaceutical manufacturers competing for the new crown vaccine track. The market pattern of foreign new crown vaccine may take shape initially, and it is not ruled out that China will follow up soon.

Before the new outbreak, the global vaccine industry was dominated by four major companies, namely GlaxoSmithKline, Merck, Sanofi and Pfizer, monopolizing about 90% of the global vaccine market revenue. In 2019, the global vaccine market is about US $32.6 billion, accounting for only about 3% of the global pharmaceutical industry.

After the global outbreak, the rapid growth of vaccine demand and huge vaccine supply gap have become two sides of the global epidemic response. The messenger RNA (mRNA) vaccine developed and produced by Pfizer & biontech is the first to be approved for use in the United States. After that, it was listed in the list of emergency use by the World Health Organization, becoming the first batch of new crown vaccines with "world pass", laying the foundation for the global circulation of Pfizer vaccine. According to public information, Pfizer's revenue reached 14.6 billion US dollars in the first quarter of this year, up 42% year-on-year. Its performance was mainly contributed by bnt162b2, a new crown vaccine developed in cooperation with biontech, with sales revenue reaching 3.462 billion US dollars. It is expected that the annual sales revenue will reach 26 billion US dollars. Pasteur, Merck and other traditional vaccine enterprises have withdrawn from the research and development and production of new crown vaccine.

At the same time, many small pharmaceutical companies enter the new crown vaccine track, and the whole vaccine industry is facing a turbulent "reshuffle". Moderna, AstraZeneca, Novavax and other pharmaceutical companies with low market reputation in the past developed new vaccine varieties to quickly seize the new crown vaccine market and grow into industry giants in a short period of time.

On the whole, pharmaceutical companies in China, the United States, the United Kingdom, India and other European countries have concentrated most of the production capacity of the world's new crown vaccine, corresponding to the huge market profits brought by the influx of orders from various countries.

According to the target of each company in 2021, the vaccine production capacity of Pfizer & biontech, Novavax, Johnson & Johnson and Moderna will reach at least 4.8 billion doses. In fact, public information shows that the total orders of these four companies have exceeded 4 billion doses. In addition, the UK's AstraZeneca has also won more than 2 billion doses of orders.

According to the global health innovation center of Duke University in the United States, the world needs about 11 billion doses of new coronal vaccine to achieve "population immunity". It can be seen that several large western pharmaceutical companies control nearly half of the world's vaccine supply, and FDA may tighten the emergency use authorization of the new crown vaccine, or further consolidate the current pattern of the vaccine industry.

Advantages of domestic vaccines

At present, four new crown vaccines independently researched and developed in China have been approved for the market, including three inactivated vaccines -- two from sinopharma group, one from Kexing Zhongwei, and one adenovirus vector vaccine jointly developed by kangxinuo and academician Chen Wei. Therefore, in the domestic vaccine market, Sinopharm group, Kexing Zhongwei and other manufacturers occupy the leading position.

In terms of production capacity, according to public data, the production capacity of new crown inactivated vaccine produced by Sinopharm group will reach more than 1 billion doses in 2021; The annual production capacity of Zhongwei original solution workshop (phase III) of Kexing will reach 2 billion doses after it is officially put into operation; After the new crown inactivated vaccine developed by Kangtai biology is approved, the planned production capacity is 200 million doses, and the annual output of adenovirus vaccine can reach 400 million doses; The annual production capacity of the recombinant protein vaccine approved by Zhifei biology is 300 million doses. On the whole, the production capacity of these manufacturers is close to 4 billion, occupying the majority of the domestic new crown vaccine market.

In addition, domestic vaccine manufacturers are accelerating their integration into the global vaccine market. China joined the covax program launched by the World Health Organization in October last year, promising to donate 10 million doses of vaccine to covax, and to provide vaccines to Asia Pacific and Latin American countries in two ways: donation and sale. In addition, the new crown vaccine produced by Sinopharm group has been listed in the list of emergency use by the World Health Organization, which also gives a "green light" for Chinese vaccines to enter the world market.

According to public information, by the end of April, China had exported more than 100 million doses of vaccines, provided vaccine assistance to at least 80 countries and 3 international organizations, and exported vaccines to more than 40 countries. Among them, Kexing Zhongwei has provided 260 million doses of new coronal vaccine to the world, of which more than 60% are provided to countries outside China. 65 million doses of Chinese medicine vaccine have been inoculated in 45 countries or regions.

On the 27th, China biology released the clinical data related to the third phase of two new coronal inactivated vaccines, which became the first clinical phase III data of new coronal inactivated vaccines in the world.

The results showed that after 14 days of inoculation, the two new crown inactivated vaccines produced high titers of antibodies and formed effective protection, and the neutralization antibody positive conversion rate of the whole population was more than 99%. Among them, the protective efficacy of the two new crown inactivated vaccines (bibp and wibp) were 78.1% and 72.8% respectively. The virus strains (wiv04 and HB02) were isolated from two patients in Jinyintan Hospital of Wuhan city.

There were no severe cases in both vaccine groups. The total incidence of adverse reactions was 44.2% in wiv04 group and 41.7% in HB02 group 7 days after inoculation. The incidence of adverse reactions was 16.1% and 15.5% 8-28 days after inoculation. Moreover, the two vaccines have good safety, the adverse reactions are mostly injection site pain, mild degree, transient and self limiting, and do not need special treatment.

According to the previous sinopharma Group China biology news, as of April 12, Sinopharm Group China biology two conditionally listed new crown inactivated vaccines were inoculated with more than 100 million doses in China, and no serious adverse reactions related to the vaccine were found. It is the most widely used new coronal vaccine with the largest vaccination volume in China, the best safety and the most widely used in the world.

In terms of production capacity, in order to guarantee the huge domestic and international demand for new coronavirus vaccine, in March 2021, Beijing Institute of biological products has started the construction of phase III production base, and Wuhan Institute of biological products has started the construction of phase II capacity expansion, with a total annual production capacity expected to reach 3 billion doses.